

Special Issue

Glucose Metabolism: Molecular Basis and Novel Therapies of Diabetic Complication

Message from the Guest Editors

Sebastian Meyhoefer and I are delighted to invite you to contribute a manuscript for a Special Issue of *Biomedicines*. The title of this issue will be Glucose Metabolism: Molecular Basis and Novel Therapies of Diabetic Complications and it will address important topics such as the genetic and phenotypic heterogeneity of diabetes as an underlying mechanisms for differential complications settings, the mechanistic basis for disturbed hypoglycemia awareness and cognitive defects, the causal link between diabetes and tumorigenesis or the impact on lipid metabolism and cardiovascular sequelae. We are convinced that this issue will shed further our knowledge on the mechanistic basis of diabetic complications and will also improve our understanding of how to therapeutically tackle these problems, based on a personalized approach that takes the heterogeneity of diabetes into account. We are very much looking forward to receiving your contribution, With warm regards Prof. Sebastian M. Meyhoefer

Guest Editors

Prof. Dr. Hendrik Lehnert

1. Department of Internal Medicine I, University of Lübeck, Lübeck, Germany
2. Rektorat, Paris Lodron Universität Salzburg, Salzburg, Austria

Prof. Dr. Sebastian M. Meyhöfer

1. Institute of Endocrinology and Diabetes, University of Lübeck, D-23538 Lübeck, Germany
2. German Center of Diabetes Research, D-85764 Neuherberg, Germany

Deadline for manuscript submissions

closed (31 December 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/168239

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).